Mayo Clinic researchers have validated a blood test's high precision for diagnosing patients with cognitive impairment.This non-invasive, cost-effective breakthrough, detailed in Alzheimer's & Dementia, offers much-needed hope for earlier intervention and better management.
Alzheimer's disease, a devastating neurological condition characterised by progressive memory loss and cognitive decline, affects millions worldwide. The profound impact extends beyond patients to their families and caregivers. While new treatments are emerging for individuals in the early stages of the disease, a critical challenge remains: the need for accessible, cost-effective, and accurate diagnostic tools to identify Alzheimer's sooner.
In a significant stride forward, Mayo Clinic researchers have validated the accuracy of an FDA-approved blood test that promises to revolutionise Alzheimer's diagnosis. This accessible test, suitable for use in outpatient memory clinics, demonstrated high accuracy in diagnosing the disease across a spectrum of cognitive impairments. The groundbreaking findings are published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Traditionally, diagnosing Alzheimer's disease has relied on methods such as positron emission tomography (PET) scans and spinal taps, which measure the buildup of toxic proteins in the brain. However, these procedures are often expensive and invasive, limiting their widespread applicability. The urgent need for more accessible, non-invasive, and cost-effective biomarkers – measurable indicators of a disease – has been a driving force in Alzheimer's research. This new blood test addresses that critical need, paving the way for improved diagnoses in diverse clinical settings.
The research team highlights the immense potential of their findings, stating that this blood test can significantly contribute to better identifying research participants with Alzheimer's disease brain changes, efficiently screening and selecting patients with Alzheimer's disease for clinical trials, and more effectively assessing patient response to therapy in clinical trials.
The study involved over 500 patients receiving treatment for various memory issues at the outpatient Memory Disorder Clinic at the Mayo Clinic in Florida. The diverse patient cohort included individuals with early- and late-onset cognitive impairment, typical and atypical Alzheimer's disease, Lewy body dementia, and vascular cognitive impairment. Patients ranged in age from 32 to 89, with the average age of symptom onset at 66. Alzheimer's disease was determined to be the underlying cause of symptoms in 56% of the participants. The research team also conducted serum tests to measure kidney disease, a factor that can influence plasma biomarker concentrations.
Mayo Clinic Laboratories conducted tests for two key proteins in blood plasma associated with amyloid plaque buildup, the hallmark of Alzheimer's disease: Aβ42/40 and p-tau217. The results revealed significantly higher levels of p-tau217 in patients diagnosed with Alzheimer's disease compared to those without the condition. Importantly, the researchers also observed that higher plasma p-tau217 concentrations were associated with impaired kidney function, underscoring the importance of considering this factor when interpreting blood test results.
Out of 509 patients, plasma p-tau217 concentrations were positive in 267 individuals. Notably, this included 233 out of 246 patients (95%) whose cognitive impairment was attributed to Alzheimer's disease, demonstrating the test's remarkable accuracy.
The study's compelling findings were prominently featured at the American Academy of Neurology Annual Meeting in April, generating significant interest within the medical community. This research builds upon a previous study by the Mayo Clinic Laboratories team, which demonstrated the utility of these blood tests in comparison to amyloid PET scans in research participants.
Looking ahead, Dr. Day, a lead researcher on the study, emphasised the next crucial steps. The team plans to evaluate blood-based testing in more diverse patient populations and in individuals with early Alzheimer's disease who may not yet exhibit cognitive symptoms. Furthermore, they aim to investigate disease-specific factors that could potentially alter biomarker accuracy in clinical trials.
This breakthrough in blood testing offers a promising future for Alzheimer's diagnosis, enabling earlier intervention, facilitating more effective clinical trials, and ultimately providing new hope for patients and their families.
Brazilian President Luiz Inácio Lula da Silva has offered to mediate between the U.S. and Venezuela, warning that urgent diplomatic intervention is n...
European Union leaders have agreed to borrow money collectively to fund Ukraine’s defence over the next two years, shelving plans to directly use fr...
Türkiye has enhanced its environmental and cultural conservation efforts, registering 10,503 monumental trees and 319 caves nationwide, the Ministry ...
Australia has announced a nationwide gun buyback scheme following the mass shooting at Sydney’s Bondi Beach, Prime Minister Anthony Albanese said on...
Former Iraqi President Barham Ahmed Salih has been elected by the UN General Assembly as the next High Commissioner for Refugees, beginning a five-yea...
A viral claim circulating online that Denmark requires sperm donors to have an IQ of at least 85 is misleading. While one Danish sperm bank, Donor Network, does use an IQ threshold, there is no nationwide legal requirement for donors to meet a specific level of intelligence.
Chinese scientists have unveiled a new gene-editing therapy that they say could lead to a functional cure for HIV, making it one of the most promising developments in decades of global research.
Serious cases of a disorder of the large intestine are surging among Americans younger than 50, researchers say.
In a discovery that pushes the limits of our cosmic imagination, astronomers have revealed a colossal bridge of gas and stars stretching between galaxies, accompanied by the longest tail ever observed, an intergalactic structure on a scale that rewrites what we know about the Universe.
The latest clashes between Thailand and Cambodia mark a dangerous escalation in one of Southeast Asia’s oldest and most sensitive disputes.
In the complex world of international diplomacy, the ongoing tensions between India and Pakistan have raised significant questions about the role of third-party mediation.
Petroleum products are being transported by rail from Azerbaijan to Armenia for the first time in decades. The move is hailed as a tangible breakthrough in efforts to normalise relations between the long-time rivals.
European Union leaders have agreed to borrow money collectively to fund Ukraine’s defence over the next two years, shelving plans to directly use frozen Russian sovereign assets.
In a ground-breaking development, artificial intelligence (AI) is taking on new forms in Japan, where it has extended to a more personal and intimate domain being romantic relationships.
China has announced plans to fully cover childbirth-related costs for families as authorities move to incentivise young couples to have more children.
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said on Thursday that he still hopes the U.S. administration will reconsider its decision to withdraw from the organisation next month, warning that its exit would be a loss for the world.
The United States has signed significant health cooperation agreements with Uganda and Lesotho, further strengthening bilateral relations and advancing global health initiatives, the U.S. State Department announced on Wednesday.
A viral claim circulating online that Denmark requires sperm donors to have an IQ of at least 85 is misleading. While one Danish sperm bank, Donor Network, does use an IQ threshold, there is no nationwide legal requirement for donors to meet a specific level of intelligence.
Chinese scientists have unveiled a new gene-editing therapy that they say could lead to a functional cure for HIV, making it one of the most promising developments in decades of global research.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment